Long‐Term Outcomes of BK Viremia in Kidney Transplant Recipients
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70333 ↗At a glance
Journal article in Clinical Transplantation, 2025. Written by Srijan Tandukar and 11 co-authors. Institution: Renal-Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, USA. Major MEDLINE topics: Kidney Transplantation, BK Virus, Viremia, Polyomavirus Infections. 29 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
BK viremia is associated with worse kidney transplant function and de novo donor‐specific antibodies (DSA), but mortality and graft survival are not impacted in the short‐ and intermediate‐term. The long‐term impact of BK viremia remains unclear.
Methods
We performed a single‐center retrospective study on 1058 consecutive kidney or kidney‐pancreas transplant recipients. We classified the cohort based on the presence or absence of BK viremia, BK viral loads, persistence of BK viremia, and pre‐existing or de novo DSA. Outcomes included mortality, graft loss, death‐censored graft survival (DCGS), estimated glomerular filtration rate, biopsy‐proven acute rejection (BPAR), de novo DSA, ureteral stenosis, and genitourinary (GU) malignancies.
Results
Over a median follow‐up period of 9.7 years, there was no difference in graft loss ( p = 0.08) and mortality ( p = 0.56). Time‐varying multivariable analysis showed no difference in DCGS [HR 1.02, (0.91–1.16)]. Compared to never BK viremic patients, patients with BK viremia had similar graft function at 5 and 10 years ( p = 0.09 and 0.65, respectively), rates of GU malignancies (7.0% vs. 5.2%, p = 0.35) and ureteral stenosis (0.8% vs. 0.4%, p = 0.63). Patients with BK viral loads >10 000 copies/mL had a higher risk of de novo DSA [HR 1.71, (1.08–2.68)] and BPAR [HR 2.11, (1.28–3.47)].
Conclusions
BK viremia did not impact mortality, graft loss, kidney function, GU malignancies, and ureteral stenosis over long‐term follow‐up, but BPAR episodes and development of de novo DSA were higher with viral loads >10 000 copies/mL. Strict monitoring protocols and immunosuppression reduction strategies are effective in minimizing the risk associated with BK viremia.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Renal-Electrolyte and Hypertension Division, Hospital of the University of Pennsylvania, Philadelphia, USA.
- Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, USA.
- University of Pennsylvania, Philadelphia, USA.
- Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, USA.
- Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, USA.
ORCID profiles: Srijan Tandukar, Jennifer Trofe, Elizabeth M Sonnenberg, Peter Abt, Vishnu Potluri
Cite
APA
Tandukar, S., Wu, Q., Chandrashekar, S., Shah, D., Chiang, C., Couch, K., Trofe, J., Sonnenberg, E. M., Abt, P., Lim, M. A., Potluri, V., & Bloom, R. (2025). Long‐Term Outcomes of BK Viremia in Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70333
Vancouver
Tandukar S, Wu Q, Chandrashekar S, Shah D, Chiang C, Couch K, et al. Long‐Term Outcomes of BK Viremia in Kidney Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70333
BibTeX
@article{Tandukar2025,
author = {Tandukar, Srijan and Wu, Qufei and Chandrashekar, Sneha and Shah, Divyash and Chiang, Chienhui and Couch, Kathryn and Trofe, Jennifer and Sonnenberg, Elizabeth M and Abt, Peter and Lim, Mary Ann and Potluri, Vishnu and Bloom, Roy},
title = {Long‐Term Outcomes of BK Viremia in Kidney Transplant Recipients},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70333}
}
EUVIMED